RE: Chinese Top Up18 Jan 2022 09:46
"As a result, it was necessary to fully utilise the supply of LFTs available under tender C40441 and then increase the volume of LFTs available under that tender to 713,500,000. "
"No further tender process was required to implement this modification"
They got the award of an additional 113M lfts without having to tender, at an increased price. Its hard to know for sure but one interpretation is that the the 713M units cost Β£322M. Another interpretation is that the (unspecified) remainder of the 600M original tender, plus the 113M extra units, was Β£322M.
713M lfts from Innova since August, who knows how many Orient Gene/ Flowflex. UK was never going to be able to provide the volumes required, so if you are buying 1B+ tests from 2 companies in China in a 6 month period,why go to all the hassle of buying 50M from a UK company at more cost and now you have another variation to deal with.
ODX never stood a chance.